The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuartix Tech Regulatory News (QTX)

Share Price Information for Quartix Tech (QTX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 140.00
Bid: 135.00
Ask: 145.00
Change: 0.00 (0.00%)
Spread: 10.00 (7.407%)
Open: 140.00
High: 140.00
Low: 140.00
Prev. Close: 140.00
QTX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Konetik update

11 Dec 2023 07:00

RNS Number : 2500W
Quartix Technologies PLC
11 December 2023
 

Quartix Technologies plc

("Quartix", "the Group" or "the Company")

Konetik update.

The Company announced the acquisition of Konetik on 15 September 2023. As noted in the trading update of 6 October 2023, a detailed review of the acquisition of Konetik Deutschland GmbH ("Konetik") and the potential for the Company's Evolve product line, a tool that assists fleet managers with planning their migration to electric vehicles, has now been completed. Following his return to the Company and appointment to the Board as Chairman on 26 September 2023, Andy Walters, major shareholder and founder of the Company, led this review.

Launched in 2022, the Evolve product has been sold as an upgrade to a small number of existing customers, principally in the UK public sector, and revenue generated to date has been very limited. Whilst users are pleased with reports provided by Evolve, repeat usage by most has been very low and renewal rates for early adopters has been disappointing. Following the review, the board considers that the ability to increase the customer base and scale the business in the next two years will be substantially more challenging than had been envisaged at the time of making the acquisition. This is due to:

1. demand for Evolve, particularly in the private sector, has been adversely impacted by delays to EV transition deadlines with the UK government's decision to postpone the ban on the sale of petrol and diesel vehicles to 2035.

2. the ability to generate substantial increases in the volume of license sales is now expected to require much higher investment in the software infrastructure due to limitations in the scalability of the current product

3. the customer acquisition cost and implementation support are now expected to be much higher than previously anticipated

4. the customer lifetime is now expected to be significantly shorter than previously anticipated

 

In addition, the Board considers that the Evolve product is not an effective tool for the acquisition of new vehicle tracking customers. Finally, the anticipated resource requirements for the development, sale, support and maintenance of Evolve means that such investment is not anticipated to achieve an appropriate return.

Following this review the Board is committed to reducing the impact of this acquisition on the operating performance of the Company as soon as possible. However, a further consequence of the conclusion of the review is, regrettably, that a substantial, one time, non-cash impairment in the goodwill arising from the Konetik acquisition (£2.5 million) will need to be made in the Company's 2023 financial statements. 

Quartix generates strong recurring revenues and operational cashflows from its subscription base and the Company will refocus its efforts on its primary strategic objective of delivering profitable growth in this core business.

Andy Walters, Executive Chairman, commented:

"Quartix provides subscription-based telematics services to more than 26,000 customers, for more than a quarter of a million commercial vehicles. Over the past 5 years Quartix has added new territories and developed additional channels to market which offer exciting growth potential for the future.

Since my return to the Company at the end of September I have been very grateful for the support of the executive management team in conducting this review and am delighted that I have their full commitment to returning the Company's focus to its core business."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended.

 

For further information, please contact:

Quartix (www.quartix.net)

Andy Walters, Executive Chairman

Emily Rees, Chief Financial Officer

01686 806 663

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Matt Goode / Seamus Fricker (Corporate Finance)

Tim Redfern / Sunila de Silva (Corporate Broking)

020 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFFFIIFSLTIIV
Date   Source Headline
9th Mar 20203:47 pmRNSPDMR Share Transfer
24th Feb 20207:00 amRNSFinal Results
13th Jan 20207:00 amRNSTrading Statement
23rd Oct 20197:00 amRNSDirectorate Changes
24th Jul 20197:00 amRNSInterim Results
19th Jun 20197:00 amRNSTrading Update
14th May 20198:58 amRNSDirector/PDMR Shareholding
10th May 20195:52 pmRNSHolding(s) in Company
15th Apr 201912:32 pmRNSDirector/PDMR Shareholding
15th Apr 20197:00 amRNSSenior Appointments
28th Mar 20198:43 amRNSDirector/PDMR Shareholding
26th Mar 20197:00 amRNSAGM Trading Statement
5th Mar 20197:00 amRNSHolding(s) in Company
25th Feb 20197:00 amRNSFinal Results
22nd Feb 20197:00 amRNSChange of Registered Office
30th Jan 20199:11 amRNSHolding(s) in Company
10th Jan 20197:00 amRNSTrading Statement
5th Dec 20187:00 amRNSExercise and Granting of Options
4th Dec 20187:00 amRNSTrading Statement
4th Oct 20187:00 amRNSBoard Update
13th Aug 20184:12 pmRNSExercise of Options
25th Jul 20187:00 amRNSInterim Results
2nd Jul 20187:00 amRNSTrading Statement
26th Apr 20182:58 pmRNSDirector Share Transfer
23rd Apr 20187:00 amRNSQueen?s Award for Enterprise
27th Mar 20182:46 pmRNSExercise of Options
27th Mar 20182:42 pmRNSResult of AGM
27th Mar 20187:00 amRNSTrading Statement
12th Mar 20186:10 pmRNSDirector/PDMR Shareholding
26th Feb 20187:00 amRNSFinal Results
16th Jan 20185:33 pmRNSDirector/PDMR Shareholding
12th Jan 20187:00 amRNSTrading Statement
1st Dec 20171:29 pmRNSIssue of Equity & Directorate Changes
10th Nov 20177:00 amRNSHolding(s) in Company
8th Nov 20173:25 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSDirectorate Change
1st Aug 20177:00 amRNSDirector/PDMR Shareholding
26th Jul 20177:00 amRNSDirectorate Changes
26th Jul 20177:00 amRNSInterim Results
3rd Jul 20177:00 amRNSTrading Update
21st Jun 20177:00 amRNSExercise of Options
18th Apr 201712:20 pmRNSDirector/PDMR Shareholding
13th Apr 20175:00 pmRNSHolding(s) in Company
30th Mar 201712:20 pmRNSHolding(s) in Company
30th Mar 20178:01 amRNSHolding(s) in Company
28th Mar 20171:20 pmRNSExercise of Options
28th Mar 201711:40 amRNSResult of AGM
28th Mar 20177:00 amRNSAGM Statement
9th Mar 201710:10 amRNSExercise of Options
2nd Mar 201711:13 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.